文献速递脊柱关节炎

依奇珠单抗单用或联合传统合成改善病情抗风湿药治疗对肿瘤坏死因子抑制剂应答不足或不耐受的活动性银屑病关节炎患者有效

Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors.
PubMed 文献 · RMD Open · 2018-09-07

SPIRIT-P2研究的事后亚组分析,按基线是否使用传统合成改善病情抗风湿药(cDMARDs,含甲氨蝶呤)分层,比较依奇珠单抗80mg每4周或每2周与安慰剂治疗活动性银屑病关节炎且既往肿瘤坏死因子抑制剂(TNFi)应答不足或不耐受患者的疗效与安全性。无论背景cDMARD状态如何,依奇珠单抗组第24周ACR20、ACR50、MDA应答率及DAS28-CRP、DAPSA改善均显著优于安慰剂。各亚组不良事件、严重不良事件及因不良事件停药比例与SPIRIT-P2总体人群相当。

要点

  • 无论是否联用cDMARDs,依奇珠单抗每4周或每2周组ACR20、ACR50、MDA应答率均显著高于安慰剂。
  • 各亚组DAS28-CRP与DAPSA相对安慰剂均显著改善。
  • 各亚组安全性(不良事件、严重不良事件、因不良事件停药)与SPIRIT-P2总体人群相当。

核心结论

  • 依奇珠单抗单用或联合cDMARDs治疗活动性银屑病关节炎且既往TNFi应答不足或不耐受患者有效,亚组安全性特征与SPIRIT-P2总体人群一致。

研究设计与样本

  • SPIRIT-P2(NCT02349295)的亚组分析,患者随机接受安慰剂、依奇珠单抗80mg每4周或每2周。
  • 按基线cDMARD使用情况分为三个亚组:任何背景cDMARDs(包括甲氨蝶呤)、仅背景甲氨蝶呤。

主要发现

  • 无论背景cDMARD状态如何,依奇珠单抗每4周或每2周组第24周ACR20、ACR50和MDA应答率均显著高于安慰剂。
  • 各亚组中DAS28-CRP和DAPSA相对安慰剂均观察到显著改善。
  • 无论背景cDMARD状态如何,依奇珠单抗每4周组身体功能相对安慰剂显著改善,依奇珠单抗每2周单药治疗亦显著改善。
  • 各亚组报告的治疗中出现的不良事件、严重不良事件(包括严重感染)及因不良事件停药百分比与SPIRIT-P2总体人群相当。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To conduct subset analyses of SPIRIT-P2 (Standard Protocol Items: Recommendations for Interventional Trials, NCT02349295) to investigate the efficacy and safety of ixekizumab versus placebo in three subgroups of patients with active psoriatic arthritis (PsA) according to the concomitant conventional synthetic disease-modifying antirheumatic drug (cDMARD) received: any background cDMARDs (including methotrexate), background methotrexate only. METHODS: Patients were randomised to receive placebo, ixekizumab 80 mg every 4 weeks (IXEQ4W) or every 2 weeks (IXEQ2W). Efficacy and safety were assessed when patients were subdivided according to cDMARD use at baseline. Efficacy was evaluated versus placebo at week 24 by the American College of Rheumatology criteria (ACR20/50), achievement of minimal disease activity (MDA) state, DiseaseActivityIndex for PsA (DAPSA), 28-joint DiseaseActivityScore using C reactive protein (DAS28-CRP), HealthAssessmentQuestionnaire-Disability Index and the 36-item Short-Form health survey physical functioning domain. RESULTS: Regardless of background cDMARD status, ACR20, ACR50 and MDA response rates were significantly higher than placebo with IXEQ4W or IXEQ2W treatment. Similarly, significant improvements were observed relative to placebo for DAS28-CRP and DAPSA across subgroups. Physical function also significantly improved relative to placebo with IXEQ4W treatment regardless of background cDMARD status and with IXEQ2W alone. Percentages of reported treatment emergent adverse events (AEs), serious AEs (including serious infections) and discontinuations due to AEs in each subgroup were comparable to the overall SPIRIT-P2 population. CONCLUSION: Ixekizumab was efficacious in patients with active PsA and previous tumour necrosis factor inhibitor (TNFi)inadequate response or TNFi intolerance treated with ixekizumab alone or when added to cDMARDswith subgroup safety profiles that were consistent with that observed in the overall SPIRIT-P2 population.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Nash P, Behrens F, Orbai AM, et al. Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors. RMD Open. 2018. PMID: 30233812. doi:10.1136/rmdopen-2018-000692

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。